Welcome to CDC Stacks | Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection--United States, 2003 - 7296 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection--United States, 2003
  • Status:
    current
  • Source:
    MMWR. Morbidity and mortality weekly report. 2003; 52(31):735-9.
Filetype[PDF - 587.17 KB]


Details:
  • Keywords:
  • Description:
    A previously published report provided guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis (TB). Protease inhibitors and NNRTIs are antiretroviral agents that are substrates that may inhibit or induce cytochrome P-450 isoenzymes (CYP450). Rifamycins are antituberculosis agents that induce CYP450 and may decrease substantially blood levels of the antiretroviral drugs. The pharmacologic interactions are called "drug-drug" because, in addition to the effect rifamycins have on protease inhibitors and NNRTIs, the antiretroviral agents may affect the blood levels of rifamycins. This notice presents updated data pertaining to drug-drug interactions between these agents and recommendations for their use from a group of CDC scientists and outside expert consultants.

  • Collection(s):
    Guidelines and Recommendations
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Controlling tuberculosis in the United States; recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America
    Personal Author:
    Blumberg, Henry M.; Nolan, Charles M.; Taylor, Zachary;
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.); American Thoracic Society; Infectious Diseases Society of America;
    Published:
    November 4, 2005
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 54, no. RR-12
    Description:
    During 1993-2003, incidence of tuberculosis (TB) in the United States decreased 44% and is now occurring at a historic low level (14,874 cases in 2003). The Advisory Council for the Elimination of Tuberculosis has called for a renewed commitment to e...
    File Type:
    Filetype[PDF - 1.11 MB]
  2. Controlling Tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America
    Corporate Author:
    National Center for HIV, STD, and TB Prevention, CDC, USA.
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2005; 54(RR-12):1-81.
    Description:
    Since the mid-1990s, public health laboratories have improved tuberculosis (TB) test performance, which has contributed to the resumption of the decline in TB incidence in the United States. However, to eliminate TB in the United States, further impr...
    Status:
    current
    File Type:
    Filetype[PDF - 1.11 MB]
  3. Treatment of tuberculosis; American Thoracic Society, CDC, and Infectious Diseases Society of America
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.); American Thoracic Society; Infectious Diseases Society of America;
    Published:
    June 20, 2003
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 52, no. RR-11
    American journal of respiratory and critical care medicine ; v. 167, p. 603-662
    Description:
    "This report appeared in the American Journal of Respiratory and Critical Care Medicine (2003;167:603--62) and is being reprinted as a courtesy to the American Thoracic Society, the Infectious Diseases Society of America, and the MMWR readership. "
    File Type:
    Filetype[PDF - 1.46 MB]
  4. Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use - United States, 2013
    Personal Author:
    Iademarco, Michael F.
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.
    Published:
    October 18, 2013
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 62, no. no. 41, p. 821-7
    Description:
    In August 2013, the Food and Drug Administration (FDA) permitted marketing of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, California) to detect DNA of the Mycobacterium tuberculosis complex (MTBC) and genetic mutations associated with resistance to ...
    Status:
    current
    File Type:
    Filetype[PDF - 283.94 KB]
  5. Treatment of latent tuberculosis infection and tuberculosis disease
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.
    Published:
    2016
    Series:
    Self-study modules on tuberculosis ; module 4
    Description:
    In this module, you will learn about the principles of treating latent TB infection (LTBI) and TB disease. A person with LTBI is treated to prevent them from progressing to TB disease. Some people with LTBI are at very high risk of developing TB dise...
    File Type:
    Filetype[PDF - 2.73 MB]